Untitled-15.gif (104 bytes)

Untitled-14.gif (102 bytes)

Untitled-1 copy.jpg (6956 bytes)

Untitled-3.gif (134 bytes)Untitled-1.gif (112 bytes)Untitled-2.gif (130 bytes)

banner468x60aphone.gif (36698 bytes) Banner10000037

cond.gif (630 bytes)

drug.gif (458 bytes)

therapies.gif (570 bytes)    

shopping11.gif (725 bytes)

pract.gif (587 bytes)

findapractitioner.gif (1135 bytes)

about.gif (367 bytes)

Search for

Untitled-12.gif (84 bytes)

SHOPPING.gif (487 bytes)

  Bookstore
  Shopping
  Weekly Specials

features.gif (591 bytes)

  Conditions & Treatments
  Drug Interactions
  Alternative Therapies
  Practitioners Directory
  Herbs
  Drugs
  Supplements
  Depletions
  Cross-Reference Guide
  Medical Terms
  Forums
  Medical Research
  HealthGrade Reports
  Herb & Dietary  Suppl.
  News & Events
  User Submissions
  Careers
  Contact Us
  About Us

pro.gif (466 bytes)

  HealthCare   Directory
  Free Web Sites
  Post a profile
  NetWords

Untitled-13.gif (74 bytes)

Untitled-12.gif (84 bytes)

  Phenylalanine

Phenylalanine

Phenylalanine is an essential amino acid that you need to get from food because your body cannot make enough of it. In healthy people, the body changes phenylalanine into tyrosine, which in turn makes important hormones, such as norepinephrine and epinephrine. Adults use about 90 percent of the phenylalanine consumed to make tyrosine, children about 40 percent. Phenylalanine may be used to treat pain, depression, multiple sclerosis, Parkinson's disease, rheumatoid arthritis, osteoarthritis, and even cancer.

Phenylketonuria (PKU) is a disorder in which the body fails to turn phenylalanine into tyrosine properly. This disease appears in infants about 3 to 6 months old, often causing severe mental retardation. It may also cause seizures and hyperactivity. Some people with PKU have a skin rash, such as eczema. PKU occurs in approximately 1 in 10,000 Caucasian infants and 1 in 132,000 African-American infants. In the United States, newborns are tested for PKU during the first 48 hours of life. PKU must be treated before the infant is 3 months old if it is to be treated successfully.

People with PKU must eat a phenylalanine-restricted, tyrosine-supplemented diet to have optimum brain development and growth. Experts disagree about whether people with PKU can discontinue this diet without problems and, if so, at what age. Mental performance and intelligence is better in those who have stayed on the diet, according to some studies. Consult your health care provider about the pros and cons of treatment.

Pregnant women with untreated PKU give birth to small infants with birth defects. These birth defects are often severe, and these infants may not live long. If you have PKU and you are, or may become, pregnant, you should be on a phenylalanine-restricted diet.

Too little phenylalanine may cause confusion, emotional agitation, depression, decreased alertness, decreased memory, behavioral changes, decreased sexual interest, bloodshot eyes, cataracts, decreased insulin, decreased skin melanin (pigment), and increased appetite. If you are getting too little phenylalanine, you should take supplemental phenylalanine and tyrosine. Otherwise, you may fail to gain weight or grow taller, lose your hair, have problems with your bones, get anemia, or even die.

Uses

  • Cancer: You may reduce tumor growth and metastasis, particularly in malignant melanoma (skin cancer), by getting less phenylalanine and tyrosine.
  • Depression
  • Inflammation
  • Multiple sclerosis: You may improve bladder control, increase mobility, and reduce depression.
  • Pain: You may be able to reduce chronic pain, particularly in osteoarthritis.
  • Parkinson's disease: You may improve rigidity, walking disabilities, and speech difficulties.
  • Vitiligo: You may improve the condition with a combination of oral L-phenylalanine, topical cream containing phenylalanine, and ultraviolet-A radiation.

Dietary Sources

  • Cheeses
  • Nuts and seeds
  • Milk chocolate
  • Meat (excluding fat), particularly organ meats
  • Poultry (excluding skin)
  • Fish, including shellfish
  • Milk
  • Eggs
  • Aspartame (Nutrasweet)

Some of the most concentrated sources of phenylalanine are torula yeast, soybean protein isolate and concentrate, peanut flour, dried spirulina seaweed, defatted and low-fat soybean flour, dried and salted cod, dried and frozen tofu, Parmesan cheese, almond meal, dry roasted soybean nuts, dried watermelon seeds, and fenugreek seeds.

Other Forms

  • D-phenylalanine
  • L-phenylalanine
  • D,L-phenylalanine (50/50 blend of D-phenylalanine and L-phenylalanine)
  • Topical creams

How to Take It

The recommended dietary allowances for phenylalanine plus tyrosine include the following.

  • Birth to 4 months: 125 mg per kilogram of body weight a day
  • 5 months to 2 years: 69 mg per kilogram of body weight a day
  • 3 to 12 years: 22 mg per kilogram of body weight a day
  • Adults and teenagers: 14 mg per kilogram of body weight a day

Some experts say that adults need 39 mg per kilogram of body weight a day.

Talk with your health care provider about dosages for specific uses. Generally, nutritional doses are 0.75 to 2 g a day and therapeutic doses are 2 to 3 g a day. Supplements are usually taken 15 to 30 minutes before meals.

Precautions

  • Anxiety, headaches, and hypertension are possible side effects.
  • People with PKU and women who are lactating or are pregnant should not take phenylalanine supplements.
  • L-dopa competes with phenylalanine for absorption and should not be taken at the same time of day.
  • Little is known about the use of aspartame (Nutrasweet) during pregnancy. Talk with your health care provider about using this artificial sweetener.
  • Doses in excess of 5 g a day may be toxic.

Possible Interactions

The absorption of baclofen, a medication used to relieve muscle spasms, may be inhibited by phenylalanine. Therefore, it is best to avoid taking this medication with a meal, especially one that is high in protein content.

Phenylalanine may reduce the effectiveness of levodopa, a medication used in combination with carbidopa for the treatment of Parkinson’s disease.

Supporting Research

Bugard P, Bremer HJ, Buhrdel P, et al. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur J Pediatr. 1999;158:46–54.

Cejudo-Ferragud E, Nacher A, Polache A, Ceros-Fortea T, Merino M, Casabo VG. Evidence of competitive inhibition for the intestinal absorption of baclofen by phenylalanine. Int J Pharmaceutics. 1996;132:63-69.

Doudet DJ, McLellan CA, Aigner TG, Wyatt RJ, Cohen RM. Delayed L-phenylalanine infusion allows for simultaneous kinetic analysis and improved evaluation of specific-to-nonspecific fluorine-18-DOPA uptake in brain. J Nucl Med. 1992;33(7):1383-1389.

Ensminger AH, Ensminger ME, Konlande JE, Robson JRK. Foods & Nutrition Encyclopedia. 2nd ed. Baton Rouge, Fla: CRC Press, Inc; 1994:1,2:60–64, 1,748.

Garrison Jr RH, Somer E. The Nutrition Desk Reference. 3rd ed. New Canaan, Conn: Keats Publishing, Inc; 1995:39–52.

Haas EM. Staying Healthy With Nutrition. Berkeley, Calif: Celestial Arts Publishing; 1992.

Herbert V, Subak-Sharpe GJ, eds. Total Nutrition (Mount Sinai School of Medicine). New York, NY: St. Martin's Press; 1995:318–320.

Newstrom H. Nutrients Catalog. Jefferson, NC: McFarland & Co; 1993:303–312.

Pietz J. Neurological aspects of adult phenylketonuria. Curr Opin Neurol. 1998;11:679–688.

Pietz J, Dunckelmann R, Rupp A, et al. Neurological outcome in adult patients with early-treated phenylketonuria. Eur J Pediatr. 1998;157:824–830.

Shils ME, Olson JA, Shike M, Ross AC. Modern Nutrition in Health and Disease. 9th ed. Baltimore, Md: Williams & Wilkins; 1999:41, 1,010.

Start K. Treating phenylketonuria by a phenylalanine-free diet. Prof Care Mother Child. 1998;8:109–110.

Werbach MR. Nutritional Influences on Illness. 2nd ed. Tarzana, Calif: Third Line Press; 1993:159–160, 384, 434, 494–495, 506, 580, 613–614, 636.

Woodward WR, Olanow CW, Beckner RM, et al. The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: Plasma and ventricular CSF L-dopa levels and clinical responses. Neurology. 1993;43:1704-1708.


Copyright © 2000 Integrative Medicine Communications

The publisher does not accept any responsibility for the accuracy of the information or the consequences arising from the application, use, or misuse of any of the information contained herein, including any injury and/or damage to any person or property as a matter of product liability, negligence, or otherwise. No warranty, expressed or implied, is made in regard to the contents of this material. No claims or endorsements are made for any drugs or compounds currently marketed or in investigative use. This material is not intended as a guide to self-medication. The reader is advised to discuss the information provided here with a doctor, pharmacist, nurse, or other authorized healthcare practitioner and to check product information (including package inserts) regarding dosage, precautions, warnings, interactions, and contraindications before administering any drug, herb, or supplement discussed herein.

           
                                                    

                         

                                

In partnership with
HRFlogo.gif (4883 bytes)

Copyright (c) 2001 AlternativeDr.com
To comment on this site, send e-mail to webmaster@alternativedr.com
Advertise with us